Is Lytgobi the Same as Futibatinib?
Yes, Lytgobi is the brand name for futibatinib, a selective FGFR inhibitor used to treat adults with unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements.[1]
What Is Lytgobi Approved For?
The FDA approved Lytgobi (futibatinib) in 2022 for previously treated FGFR2-altered cholangiocarcinoma based on the FOENIX-CCA2 trial, which showed a 42% objective response rate and median duration of 9.7 months.[1][2]
How Does Futibatinib Work?
Futibatinib targets fibroblast growth factor receptor 2 (FGFR2), blocking signaling in tumors with FGFR2 fusions or other alterations common in 10-16% of intrahepatic cholangiocarcinomas.[1]
Who Makes Lytgobi and When Did It Launch?
Taiho Oncology markets Lytgobi in the US. It became available shortly after FDA approval in October 2022.[1]
Futibatinib Patent Status and Exclusivity
Lytgobi's key composition-of-matter patent (US 8,410,157) expires in 2031, with pediatric exclusivity extending market protection to January 2032. Taiho holds additional patents on methods of use and formulations through the late 2030s.3
Common Side Effects Patients Report
Hyperphosphatemia (84% of patients), dry mouth (58%), diarrhea (56%), and nail toxicity (52%) are frequent. Serious risks include retinal disorders and infections; monitoring phosphate levels is required.[1][2]
How Does It Compare to Other FGFR Inhibitors?
| Drug (Brand) | Target | Approval Year | Key Trial ORR | Phosphate Management |
|--------------|--------|---------------|---------------|----------------------|
| Futibatinib (Lytgobi) | FGFR1-4 | 2022 | 42% (FOENIX-CCA2) | Dose adjustments |
| Pemigatinib (Pemazyre) | FGFR2/1/3 | 2020 | 37% (FIGHT-202) | Similar monitoring |
| Infigratinib (Truseltiq) | FGFR1-3 | 2021 | 25% (FIGHT-302) | Dose adjustments |
Futibatinib shows higher response rates in FGFR2 fusion-positive cases but similar toxicity profiles.[2]
[1]: FDA Prescribing Information for Lytgobi (taihooncology.com)
[2]: NEJM (2023): FOENIX-CCA2 trial results